Alnylam price target raised to $475 from $405 at Morgan Stanley

Morgan Stanley analyst Michael Ulz raised the firm’s price target on Alnylam (ALNY) to $475 from $405 and keeps an Equal Weight rating on the shares. The firm, which notes that its monthly sales and script analysis implies Q3 worldwide Amvuttra sales of about $650M-$680M, which would be “notably above” the consensus estimate of $608M, sees the potential for “another beat and raise” in Q3 as it expects Amvuttra launch momentum in TTR-CM to continue.